Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors

• Status: Recruiting
• Trial end date: 2023-02-10

Summary

This is a multi-center phase II clinical trial to evaluate the anti-tumor activity and safety of HX009 in subjects with advanced solid tumors.

• Phase: Phase 2

Details

• Lead Sponsor: Waterstone Hanxbio Pty Ltd